HSTO.Q Stock Overview
A clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Histogen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.025 |
| 52 Week High | US$0.55 |
| 52 Week Low | US$0.02 |
| Beta | 0.80 |
| 1 Month Change | 25.00% |
| 3 Month Change | -88.10% |
| 1 Year Change | -92.06% |
| 3 Year Change | -99.62% |
| 5 Year Change | n/a |
| Change since IPO | -99.97% |
Recent News & Updates
Recent updates
Histogen stock down 8% after Q2 loss, on track for six-day losing streak
Aug 12Histogen announces pricing of $5M private placement
Jul 12We're A Little Worried About Histogen's (NASDAQ:HSTO) Cash Burn Rate
Dec 02
Histogen jumps 11% after Intracoastal Capital reports 5.6% stake
Jun 16Histogen enters $6.5M at-the-market direct offering
Jun 07Histogen under pressure on pricing $14M upsized public offering
Dec 31Histogen files IND application for regenerative human matrix
Dec 17Histogen soars after HST-001 data in male pattern baldness
Dec 01Shareholder Returns
| HSTO.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.6% | 2.8% |
| 1Y | -92.1% | -3.3% | 24.6% |
Return vs Industry: HSTO.Q underperformed the US Biotechs industry which returned -3.8% over the past year.
Return vs Market: HSTO.Q underperformed the US Market which returned 24.5% over the past year.
Price Volatility
| HSTO.Q volatility | |
|---|---|
| HSTO.Q Average Weekly Movement | 40.6% |
| Biotechs Industry Average Movement | 10.7% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.4% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: HSTO.Q's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: HSTO.Q's weekly volatility (41%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 7 | Susan Knudson | www.histogen.com |
Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body’s natural process to restore immune function. The company’s product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases.
Histogen Inc. Fundamentals Summary
| HSTO.Q fundamental statistics | |
|---|---|
| Market cap | US$106.79k |
| Earnings (TTM) | -US$12.38m |
| Revenue (TTM) | US$19.00k |
5.6x
P/S Ratio0.0x
P/E RatioIs HSTO.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HSTO.Q income statement (TTM) | |
|---|---|
| Revenue | US$19.00k |
| Cost of Revenue | US$3.28m |
| Gross Profit | -US$3.26m |
| Other Expenses | US$9.12m |
| Earnings | -US$12.38m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.90 |
| Gross Margin | -17,152.63% |
| Net Profit Margin | -65,142.11% |
| Debt/Equity Ratio | 0% |
How did HSTO.Q perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 11:27 |
| End of Day Share Price | 2024/12/26 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Histogen Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Newman | Canaccord Genuity |
| Douglas Tsao | H.C. Wainwright & Co. |